Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest Data For Edwards’ Sapien Suggest Steep Learning Curve For Doctors

This article was originally published in The Gray Sheet

Executive Summary

Analysts are disappointed with the mortality data in European registries of Edwards Lifesciences' Sapien transcatheter aortic heart valve, but are optimistic that outcomes will improve in the U.S. trial as physicians get better at implanting the device
Advertisement

Related Content

Heart Valve Market: PAVR Poised for Growth
Vying Valves: Edwards’ Sapien Progresses, But CoreValve Remains A Threat
Vying Valves: Edwards’ Sapien Progresses, But CoreValve Remains A Threat
Edwards’ Sapien Sales Drive 24% Gain In Q2 Heart Valve Revenue
Edwards’ Sapien Sales Drive 24% Gain In Q2 Heart Valve Revenue
Advertisement
UsernamePublicRestriction

Register

MT026597

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel